Dyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc DYAI.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of three analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from -4 cents to -3 cents per share.
Revenue fell 0.6% to $961.00 thousand from a year ago; analysts expected $993.33 thousand.
Dyadic International Inc's reported EPS for the quarter was a loss of 6 cents.
The company reported a quarterly loss of $2.12 million.
Dyadic International Inc shares had risen by 17.2% this quarter and gained 11.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 8.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
Wall Street's median 12-month price target for Dyadic International Inc is $6.00, about 82.5% above its last closing price of $1.05
This summary was machine generated from LSEG data August 12 at 09:02 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.04 | -0.06 | Missed |
Mar. 31 2026 | -0.04 | -0.05 | Missed |
Dec. 31 2025 | -0.04 | -0.06 | Missed |
Sep. 30 2025 | -0.04 | -0.06 | Missed |
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development